[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.130.145. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
January 2008

Treatment of PemphigusThe Need for More Evidence

Arch Dermatol. 2008;144(1):100-101. doi:10.1001/archdermatol.2007.14

Pemphigus vulgaris is a prototype antibody-mediated autoimmune disorder in which autoantibodies against desmosomal intraepidermal adhesion proteins lead to acantholysis and blister formation. Although our understanding of the molecular pathogenesis of pemphigus and other autoimmune bullous diseases has increased markedly in recent decades, similar progress regarding effective treatment has not been made.

There are a large number of potential interventions for pemphigus.1 The cornerstone of treatment is corticosteroids, although use of immunosuppressive agents, immunomodulatory agents, plasmapheresis, intravenous immunoglobulin, and biological agents has also been described. The efficacy and role of each of these agents has not been established.

First Page Preview View Large
First page PDF preview
First page PDF preview
×